ClearStrand-ASD is a non-invasive, laboratory-developed autism
rule-out test for infants and toddlers aged 1–48 months. It must be ordered by a licensed
healthcare provider and is run in a CLIA-certified lab.
Instead
of genetics, the test measures an objective biochemical
biomarker by reading hundreds of time points along a single
hair strand. Results are reported as:
1. Negative (biomarker not detected; ASD unlikely) or
2. Non-negative (biomarker detected; ASD cannot be ruled out).
A Negative result has a >90% negative predictive value, meaning
that in most cases a specialist would not diagnose autism for a child with a Negative result.
ClearStrand-ASD
does not replace clinical
diagnosis. It fits as an adjunct to today’s pathway, where clinicians screen first and specialists confirm. A Negative result can help shift attention to
other developmental needs, while a Non-negative result can prompt earlier referral for a
full autism evaluation and, when appropriate, earlier
access to autism-specific interventions. In short, it
supports clinicians and families in moving sooner with clearer next steps. For
more details, please visit: https://www.clearstrandasd.com/
Meta-Ex is a hybrid liquid-chromatography high-resolution mass spectrometry assay. From
a ~50 µL sample, it delivers untargeted metabolomics of endogenous pathways
while simultaneously providing targeted quantification of PFAS and selected
xenobiotics.
The
key benefit over standard metabolomics is that it measures exposures and the
body’s response in the same run, so you
use fewer tubes and avoid batch effects and other confounders. It also supports easy, low-volume sampling like dried blood spots and microsamplers. This yields publication-grade outputs
(PFAS quant tables, confident metabolite IDs, pathway analyses) that translate
quickly into targeted follow-ups and interventions.
In
research-use-only studies, Meta-Ex is a great fit for: inflammation and
autoimmune diseases (where external chemicals can shift bile-acid and lipid
pathways); NAFLD/ NASH and cardio-metabolic conditions (where pollutant burden
relates to lipid changes and oxidative stress); maternal–child and
neurodevelopment work (which benefits from tiny, at-home samples); and
kidney/endocrine studies that need paired measurements of exposures and the
body’s metabolic response.
For
more details, please contact: hello@auragen.com.sg
Mol-Ex is a gas-chromatography high-resolution mass spectrometry Exposomics assay that
detects more than 70 exogenous chemicals across over 40 classes—including
phenols, pesticides, fragrances, UV absorbers, PAHs, biphenyls, and naphthalene
derivatives—thereby capturing semi-volatile and non-polar compounds often
under-represented in LC-only workflows.
What
sets Mol-Ex apart is that it detects a wide
range of specific chemicals and actually names
them. When you view these exposure data alongside LC-based
pathway readouts, you can explain why pathways change instead of treating the
signal as noise. Because the chemicals are identified explicitly (not just
inferred), the results are immediately useful for prevention and policy decisions.
In RUO
work, common uses include: respiratory/allergy studies that link ambient triggers to airway inflammation; occupational
and environmental medicine that needs worker- or site-level
exposure profiles tied to biological effects; oncology
and survivorship projects that monitor exposure-related
toxicity; and gastroenterology / microbiome research that separates diet/chemical signals from microbial metabolites. For
more details, please contact:
hello@auragen.com.sg
© Copyright AURAGEN PTE LTD, SINGAPORE. All Rights Reserved